Table II.
Analysis of co-morbidities and the use of selected groups of drugs and performed procedures in patients with unexplained anemia, defined anemia and no anemia
| Characteristics | Whole population (n = 981) |
Unexplained anemiaa,b (n = 48) |
Defined anemiad (n = 121) |
No anemia groupc (n = 812) |
P-value | |
|---|---|---|---|---|---|---|
| Comorbidities, % (n): | ||||||
| Hypertension | 78.7 (772) | 95.8 (46) | 82.6 (100) | 77.1 (626) | 0.005 | |
| Coronary heart disease | 32.5 (319) | 62.5 (30) | 38.0 (46) | 29.9 (243) | < 0.0001 | |
| Diabetes | 25 (245) | 35.4 (17) | 29.7 (36) | 23.6 (192) | 0.08 | |
| Chronic kidney disease | 12.1 (102) | 29.6 (13) | 34.6 (36) | 7.6 (53) | < 0.0001 | |
| Heart failure | 10.8 (106) | 31.2 (15) | 23.1 (28) | 7.8 (63) | < 0.0001 | |
| Atrial fibrillation | 10.4 (102) | 20.8 (10) | 20.7 (25) | 8.2 (67) | < 0.0001 | |
| Rheumatic diseases | 1.1 (11) | 2.1 (1) | 5.0 (6) | 0.5 (4) | < 0.0001 | |
| Chronic pulmonary disease | 12.0 (118) | 6.2 (3) | 25.6 (31) | 10.3 (84) | < 0.0001 | |
| Asthma | 5.2 (51) | 0 (0) | 6.6 (8) | 5.3 (43) | 0.2 | |
| COPD | 4.0 (39) | 2.1 (1) | 9.1 (11) | 3.3 (27) | 0.008 | |
| Chronic liver diseases | 3.4 (33) | 6.2 (3) | 13.2 (16) | 1.7 (14) | < 0.0001 | |
| Thyroid diseases | 18.6 (182) | 29.2 (14) | 23.1 (28) | 17.2 (140) | 0.045 | |
| Venous thromboembolism | 3.5 (34) | 8.3 (4) | 7.4 (9) | 2.6 (21) | 0.004 | |
| Cancer | 10.3 (101) | 2.1 (1) | 35.5 (43) | 7.0 (57) | < 0.0001 | |
| Dementia syndrome | 3.4 (33) | 14.6 (7) | 6.6 (8) | 2.2 (18) | < 0.0001 | |
| Drugs, % (n): | ||||||
| Aspirin | 26.4 (259) | 58.3 (28) | 44.6 (54) | 21.8 (177) | < 0.0001 | |
| Anticoagulants (DOACs/VKA) | 9.8 (96) | 22.9 (11) | 21.5 (26) | 7.3 (59) | < 0.0001 | |
| Clopidogrel | 6.9 (68) | 25.0 (12) | 12.4 (15) | 5.0 (41) | < 0.0001 | |
| Procedures*, % (n): | ||||||
| Coronary angiography | 10.0 (98) | 27.1 (13) | 19.0 (23) | 7.6 (62) | < 0.0001 | |
| PTCA | 6.1 (60) | 14.6 (7) | 11.6 (14) | 4.8 (39) | 0.0006 | |
A significantly greater value in the UA group than the NA group for the following parameters: hypertension and thyroid diseases. bA significantly greater value in the UA group than the DA group and the UA group than the NA group for the following parameter: coronary heart disease. cA significantly lower value in the NA group than the UA group and the DA group for the following parameters: chronic kidney disease, heart failure, atrial fibrillation, aspirin, anticoagulants (DOACs/VKA), coronary angiography, PTCA, chronic liver diseases, venous thromboembolism, dementia syndrome, clopidogrel. dA significantly greater value in the DA group than the UA group for COPD. COPD – chronic obstructive pulmonary disease, DA – defined anemia, DOAC – direct oral anticoagulants, NA – no anemia, PTCA – percutaneous transluminal coronary angioplasty, UA – unexplained anemia, VKA – vitamin K antagonist. A p-value less than 0.05 was considered statistically significant. *The subject of analysis was whether the procedure was performed in a patient at least once and not the number of procedures performed in the patient.